These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3378957)

  • 41. Antimicrobial resistance and resistance transfer in anaerobic. A review.
    Tally FP; Malamy MH
    Scand J Gastroenterol Suppl; 1984; 91():21-30. PubMed ID: 6377471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    J Clin Microbiol; 1987 Apr; 25(4):645-9. PubMed ID: 3571474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):946-9. PubMed ID: 1486894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Apr; 32(4):601-4. PubMed ID: 3163908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is ciprofloxacin active against clinically important anaerobes?
    Watt B; Brown FV
    J Antimicrob Chemother; 1986 May; 17(5):605-13. PubMed ID: 2941400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Standardization of antimicrobial disc susceptibility test for anaerobic bacteria.
    Ho SW
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1976 Dec; 9(3-4):55-62. PubMed ID: 1037535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of antimicrobial resistance and resistance transfer in anaerobic bacteria.
    Tally FP; Malamy MH
    Scand J Infect Dis Suppl; 1982; 35():37-44. PubMed ID: 6300995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial susceptibility profiles of invasive isolates of anaerobic bacteria from a large Canadian reference laboratory: 2012-2019.
    Forbes JD; Kus JV; Patel SN
    Anaerobe; 2021 Aug; 70():102386. PubMed ID: 34044100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibiotic susceptibility of anaerobic bacteria in Europe.
    Tunér K; Nord CE
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S387-9. PubMed ID: 8324153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bactericidal activity of chloramphenicol, clindamycin, metronidazole and cefoxitin against Bacteroides fragilis.
    Soriano F; Ponte M; García-Hierro P
    J Antimicrob Chemother; 1980 Sep; 6(5):679-80. PubMed ID: 7410288
    [No Abstract]   [Full Text] [Related]  

  • 54. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1064-7. PubMed ID: 2559846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteria.
    Wexler HM; Finegold SM
    Eur J Clin Microbiol; 1987 Aug; 6(4):492-4. PubMed ID: 2959473
    [No Abstract]   [Full Text] [Related]  

  • 59. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.